New weekly shot aims to boost growth in teens with dwarfism
NCT ID NCT06732895
Summary
This trial is testing whether a new weekly injection called navepegritide can safely increase the annual growth rate in adolescents (ages 12-18) with achondroplasia, a genetic condition that causes dwarfism. About 24 participants will receive either the active drug or a placebo (inactive shot) for one year. The main goal is to see if the treatment helps teens grow taller faster than they would without it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGMontreal, H3T 1C5, Canada
-
Ascendis Investigational Site
RECRUITINGCopenhagen, 2100, Denmark
-
Ascendis Investigational Site
RECRUITINGParis, 75743, France
-
Ascendis Investigational Site
RECRUITINGDublin, D01 YC76, Ireland
-
Ascendis Investigational Site
RECRUITINGNorwich, NR4 7UY, United Kingdom
Conditions
Explore the condition pages connected to this study.